Epigenetic and microRNA-mediated regulation in diabetes

Pirkko Muhonen and Harry Holthofer

Centre for BioAnalytical Sciences, Dublin City University, Glasnevin, Dublin 9, Ireland

Keywords: diabetes; epigenetics; microRNA; podocyte

Introduction

The increase in adult type diabetes is becoming a global epidemic and calls for swift actions to better understand the disease mechanisms, thus leading to improved targeted therapies. Emerging knowledge surrounding the role of microRNAs (miRNAs) in the regulation of post-transcriptional protein expression has dramatically altered the view of how target genes are regulated and how they are involved also in controlling glucose homeostasis. In addition to an improved understanding of miRNA functions, epigenetic control mechanisms are becoming better known. Thus, for example the effect of prenatal nutritional deficiencies and hereditary epigenetic changes, including DNA methylation and histone modifications are emerging as important players in the finely tuned balance of factors ultimately yielding the altered functions under various pathologic conditions.

In this article, we review the current understanding of the major epigenetic and post-transcriptional regulatory mechanisms with particular emphasis on podocytes during their injury associated with diabetic kidney damage. It is foreseen that this research line will bring major advances in diagnostics and understanding of pathomechanisms of both type 1 and 2 diabetes and will lead to identification of novel biomarkers and therapeutic targets.

Epigenetic regulation

The term epigenetics is typically defined as heritable changes in gene expression that are not encoded directly within the DNA sequence of genes. Epigenetic changes are crucial for the development and differentiation of the various cell types in an organism. However, epigenetic states can become disrupted by environmental influences or during ageing, and the importance of epigenetic changes in the development of cancer and other diseases is increasingly being discovered.

Eukaryotic genomes are packaged in two general varieties of chromatin: gene-rich euchromatin and genetically inactive heterochromatin. Heterochromatin is a tightly packaged form of DNA, and its major characteristic is that DNA transcription is limited. Centromeres and telomeres are both heterochromatic (Figure 1). The euchromatin, in contrast, contains ‘active’ chromatin: DNA sequences that are being transcribed into RNA [1]. Heterochromatin replicates in the S phase (synthesis phase) of the cell cycle later than euchromatin, most likely preserving DNA structure during replication. Heterochromatin also maintains a compact and visible structure during mitosis therefore differing from euchromatin, which undergoes a typical cycle of condensation and unravelling during this process [2].

The DNA packaging densities of these two chromatin types vary along the length of the chromosome. High-density heterochromatin regions surround the centromeric region of the chromosome and have a low amount of
expressed genes but a high content of repetitive DNA sequences including transposons, which are mobile genetic elements, and highly repetitive DNA regions called satellite DNAs [3]. These two chromatin states are controlled by reversible epigenetic patterns of DNA methylation and histone modifications that changes gene expression without involving changes in the DNA sequence (Figure 2A and B).

Heterochromatin has diverse known and postulated functions: maintenance of genome stability, proper chromosomal segregation during mitosis and prevention of telomere fusion [4]. Heterochromatin also regulates gene expression by both repression and activation, by directly silencing genes or by removal of silencing hallmarks of gene expression [5]. These mechanisms result in considerable regulatory functions during development and in different physiologic states of cells.

In addition to the heterochromatin diversity, the mammalian genome contains well-defined sequences, which notably consist of repeats of cytosine-phosphate-guanidine (CpG) motifs. These areas were earlier considered as non-functional redundant domains of the chromosomes during evolution while recent research has revealed strong regulatory functions to these elements mainly in influencing histone modifications and gene-silencing networks within the cells [6].

In general, the epigenetic regulation of gene transcription–translation machinery consists of now known multiple mechanisms for modifying the readout of the genetic code and repression of the chromatin state. In the context of DNA methylation, sequences within the genome can be classified into two different groups: CpG-deprived regions and CpG-rich regions called ‘CpG islands’ (see Figure 2). CpG islands are defined as being longer than 500 bp and having a GC base content >55% [7]. Considering their regulatory role, CpG islands are often found in promoter regions and about half of all genes contain CpG islands that are situated at the end of the 5’ region [8]. Altered methylation status of GC-rich regions may alter the chromatin structure and typically modulates the finely tuned promoter-transcription factor interactions with the transcriptional machinery [9]. This alteration leads to repressed gene expression associated with hypermethylated CpG islands. In contrast, genomic instability and aberrant gene expression have been associated with hypomethylated islands [10]. It has been proposed that more than half of the repeating 5′-CpG island sequences ultimately participate in transcription regulation as a result of methylation [11].

Histones are core proteins involved in DNA assembly and yielding chromatin structure. Histones may dynamically undergo post-translational modifications, which alter their interaction with DNA and nuclear proteins. The flexible N-terminal tails of the four core histones (H2A, H2B, H3 and H4, see Figure 1) may undergo a range of post-translational modifications, including acetylation, methylation, O-GlcNac modification, phosphorylation and ubiquitination, all leading to changes in the gene expression level.

MicroRNA biogenesis

MicroRNAs are single-stranded transcribed RNAs of 19–25 nucleotides in length that are generated from endogenous hairpin structured transcripts throughout the genome [17]. Recent studies have shown that miRNAs have pivotal roles in diverse gene regulatory pathways, including e.g. control of timing of developmental processes [18], haematopoietic cell differentiation [19], apoptosis [20], cell proliferation
Fig. 2. Schematic figure of epigenetic regulation mechanism. DNA methylase catalyze the transfer of a methyl group to the cytosine residues in CpG dinucleotide sequences (A). Methylation of the CpG islands in the gene promoter region inhibits gene expression (B). Histone acetylation plays an important role in the regulation of gene expression. Hyperacetylated chromatin is transcriptionally active whereas hypoacetylated chromatin is silent. Methyl-CpG-binding proteins interact with histone deacetylase causing gene silencing (C).

and organ development [21]. MicroRNAs also represent one of the largest gene families, accounting for ∼2% of the whole genome [17]. Efforts to identify the specific miRNA targets have lead to speculations that miRNAs can directly regulate the imprint of >90% of human genes [22]. Their defined functions as key post-transcriptional regulatory mediators are rapidly emerging and have been shown to be involved in the pathogenesis of a variety of diseases [23], including type 2 diabetes (see Table 1). Even now little is known of direct miRNA effects in the regulation of the functional kidney filtration barrier [24].

Biogenesis of miRNAs starts in the nucleus (see Figure 3) where stretches of several kilobases long primary miRNAs (pri-miRNAs) are transcribed from the genome, 3’-polyadenylated [covalent linkage poly (A) tail of 3’ end of miRNA], 5’-capped [7-methyl guanylate (m7G) cap of 5’ end of miRNA]. Pri-miRNAs are further modified by a microprocessor that consists of Drosha, a nuclear RNaseIII enzyme, and its essential cofactor called Pasha [25]. This resulting protein complex processes pri-miRNAs into ∼70 nucleotide (nt)-long hairpin-shaped premature miRNAs (pre-miRNAs), and the subsequent cleavage at approximately two helical turns from the loop structure. Pre-miRNAs bear a two nt 3’-overhang that contributes to pre-miRNA export out of the nucleus to the cytoplasm by a RanGTP/exportin-5-dependent mechanism [26]. Dicer, a cytoplasmic RNaseIII enzyme, then subjects pre-miRNA to a second cleavage step in the cytoplasm. Dicer cleaves near the hairpin loop to release a short, ∼22 base-pair (bp)-long incomplete RNA duplex with characteristic two nt-long 3’-overhangs at both ends that anchor miRNA molecules to the miRNA-induced silencing complex miRISC [27]. The miRNA strand having lower thermodynamic stability at its 5’-end is selectively identified by miRISC and incorporated into miRISC that contains an Argonaute protein that is the catalytic component of RISC, and other protein factors [28]. When activated by miRNA, miRISC acts as an effector complex of the miRNA pathway interacting with messenger RNA (mRNA). There are several proposed and verified mechanisms regarding how these genome-originated miRNAs can modulate gene and protein expression [29]. It has been shown that miRNAs exhibiting full complementarity to target mRNA elicit mRNA degradation via a mechanism shared with short interfering RNAs (siRNAs).
Validated miRNA targets in type 2 diabetes and in the endocrine system

| miRNA  | Target                                      | Function                                      | Reference |
|--------|---------------------------------------------|-----------------------------------------------|-----------|
| miR-375| Myotrophin                                   | Inhibition of insulin secretion               | [69]      |
| miR-9  | OneCut2 transcription factor                 | Inhibition of glucose-stimulated insulin release | [70]      |
| miR-192| E-box repressors                             | TGF-beta-induced matrix protein collagen      | [24]      |
|        |                                             | Col1a1 and -2                                 |           |
| miR-143| GLUT4, HSL, fatty acid-binding protein aP2, PPAR-µ2 | Adipocyte differentiation                     | [49]      |

Hypothetic miRNA targets associated with type 2 diabetes

| miRNA family | Target                                      | Function                                      | Reference |
|--------------|---------------------------------------------|-----------------------------------------------|-----------|
| miR-30 family| Receptor for advanced glycation end product, immediate early response 3, vimentin, heat-shock protein-20 | Podocyte apoptosis and cytoskeletal structure | [79,80]   |
| miR-23b      | Hairy/enhancer of the split protein (Hes1)  | Downstream target of activated Notch signalling and expressed in nephron segments during development | [81,84]   |
| miR-15, miR-16| Wnt and β-catenin                           | Nephron induction during embryo development    | [75,76]   |
| miR-7        | Gv-box                                      | Notch signalling                              | [73,74]   |
| miR-4, miR-79| Brd-box                                     |                                              |           |
| miR-2, miR-11| K-box                                      |                                              |           |

However, in cases of non-perfect complementary binding to the target mRNA 3′-untranslated region (3′-UTR), miRISC may hinder protein translation by several different mechanisms (Figure 3). These mechanisms include translational inhibition at the level of initiation and elongation, degradation of mRNA or the immature protein products or mRNA segregation into P bodies for translational inhibition and/or by mRNA deadenylation that causes destabilization of mRNA [30–32]. The outcome of all these mechanisms either singularly or acting in combination is an effective regulation of the final mRNA yielding protein expression.

**Tools to generate epigenetic and post-transcriptional profiles**

Individual gene expression outcomes in complex diseases, typically in metabolic disorders such as type 2 diabetes, are unlikely to completely explain their impact on disease pathogenesis [33]. Multiple factors are normally needed to manifest any polygenic human disease. In addition to DNA mutations and protein post-translational modifications, well-known factors typically include a complexity of environmental, dietary and exercise factors while the epigenetic regulatory mechanisms and any combinations of the convoluted mechanisms involved appear to be responsible in an increasing number of disease outcomes [34]. Present day DNA analytics using robust techniques of, for example, genome-wide sequencing and mapping of global single nucleotide polymorphisms (SNPs), may thus not ultimately yield sufficient knowledge to understand disease pathogenesis. In combination with the new high-capacity array technologies [35], a new balance between global genomics, epigenetic gene regulation and post-transcriptional effects on protein landscape integrating the distinct data streams is needed to build a comprehensive understanding of disease development.
understanding of underlying disease mechanisms in detail [36].

The huge screening capacity provided by modern microarrays enable the study of individual factors involved in disease pathogenesis on a genome-wide scale simultaneously. A wide range of approaches is rapidly emerging to track the gene targets under epigenetic regulation and to determine the global changes in genomic DNA methylation. Customized combinations of these approaches, based on individual requirements, pave the way to an in-depth understanding of the processes involved and, hopefully, will yield better understanding for improved diagnostics and for example new targets for better therapies.

Computational public database analysis [available e.g. at National Center for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/), UCSC Genome Bioinformatics group, University of California, Santa Cruz, http://genome.ucsc.edu/] is a key step in analysing and locating CpG islands in the promoter region of genes of interest. Considerable advances have been made in hybridization-based microarray technologies for genome-wide analysis for DNA methylation that is designed to discriminate between methylated and unmethylated sequences in gene promoters [36]. A variety of other tools (see Table 2) for genome-wide discovery of differentially methylated sites include restriction mapping, bisulfite nucleotide sequencing, PCR amplification and chromatin immunoprecipitation on DNA microarray (ChIP-on-chip; for an excellent introduction, PCR amplification and chromatin immunoprecipitation include restriction mapping, bisulfite nucleotide sequencing, for example new targets for better therapies. [36].

With current microarray methods, it is also possible to monitor the effects of DNA demethylating agents (e.g. 5-aza-2′-deoxycytidine) or histone deacetylization inhibitors (HDACs) by exploring transcription profiles of reactivated genes [38]. The approaches taken to distinguish miRNA expression signatures associated with kidney disorders differ from approaches used to assay DNA methylation levels because miRNAs interfere at the post-transcriptional level while DNA methylation influences the transcription of the genome expression. In addition, it is a challenge to validate the miRNA target sequences because several different miRNAs may bind to and cooperatively control a single mRNA target and, conversely, a single miRNA can bind to and regulate many different mRNA targets [39]. Therefore, high-throughput methods supplemented with extensive in silico data analysis and the subsequent investigation of the regulation of miRNA-mediated protein translation typically consist of comparison of protein expression levels [e.g. difference gel electrophoresis (DiGE), mass spectrometry (MS) and western Blot] alongside with microRNA expression levels (miRNA arrays, qPCR) [40].

Hybridization-based microarrays to detect miRNAs are based on miRBase Sequence database (http://microrna.sanger.ac.uk/) that is a searchable database of published miRNA loci from 58 species, ranging from vertebrates and invertebrates to prokaryotes including viruses [41]. Recently, next-generation sequencing (NGS) technology has been shown to be capable of producing millions of DNA sequence reads ranging from 35 to 250 base pairs in a single run (commercially available sequencers: Roche (454) GS FLX sequencer http://www.454.com/enabling-technology/the-system.asp; Illumina/Solexa Genome analyser http://www.illumina.com/; and the Applied Biosystems SOLiD system http://marketing.appliedbiosystems.com/mk/get/SOLID_KNOWLEDGE_LANDING). This new technology provides multiple advantages when compared to gene expression microarray platforms, not least in discovering non-coding RNA sequences, especially novel miRNAs [42].

The final in vitro miRNA-target validation should be brought together by using pre-miRNA structures or miRNA inhibitors as demonstrated by Tian et al. [42] for example. Only a few in vitro validated miRNA targets have thus far been identified using the pre-miRNA hairpin structures that mimic natural miRNA molecules [43]. These pre-miRNAs are computationally predicted sequences emerging from the miRBase Sequence databases and typically increase the natural miRNA effect. Distinct pre-miRNA vector constructs as well as synthetic miRNA mimics are available commercially for miRNA functional analyses and miRNA-target site validation (e.g. Systems Biosciences, Mountain View, CA, USA: pre-miRNA clones; Dharmacon, Inc. Lafayette, CO, USA: miRIDIAN miRNA Mimic Library; Ambion, Inc. Austin TX, USA: Pre-miRTM miRNA Precursor Molecules) for extensive miRNA target validation for in vitro and in vivo purposes. Recently, it was shown that synthetic single stranded mature miRNAs or hairpin pre-miRNA structures cannot replace endogenous miRNAs already present in RISC [44]. This affects the validation of miRNA targets by exogenous miRNA mimic structures.

Antisense DNA oligonucleotides (ASOs) and anti-miRNA oligonucleotides (AMOs, antagonists) are considered as a practical approach for specific pharmacological inhibition of miRNA function [45]. There are two suggested strategies to target miRNA function in vitro and in vivo. First, ASOs are designed for RNaseH-mediated targeted degradation of pri-miRNA molecules in nucleus [46]. The stereochmistry at the 2′-position of the ribose has been shown to be a major determinant in the target RNA-binding affinity and the activation of RNaseH [47]. Most common chemical modifications are phosphorothioate (PS) backbone modification combined with 2′-O-methyl (2′-OMe) or with 2′-O-methoxyethyl (2′-O-MOE) antisense RNA oligomers or mixed locked nucleic acid (LNA)-DNA ASOs [46]. The base-pair interaction between mature miRNA and mRNA is another logical target for an inhibitor. AMOs are targeting mature mRNA molecules in cytoplasm and designed to block its function in miRISC [46]. Whereas pre-miRNA structures and unmodified single stranded mature miRNA molecules were not able to dissociate endogenous miRNAs from RISC, chemically modified ribo-oligonucleotides have been shown to present with this potential [44]. AMOs consist of chemical modifications of 2′-ribose and/or phosphate backbone (including 2′-OMe, 2′Fluoro, 2′-OMOE, LNAs and PS backbone modifications) essential in protecting AMOs against endonuclease-mediated degradation and in improving affinity to target miRNA molecules [46]. MiRNA–mRNA base-pair interaction has successfully been interrupted by transfecting modified AMOs complementary to miRNAs leading to
blockage of the miRNA–RISC complex [48]. Esau et al. applied [49] 2′-O-MOE phosphorothioate-modified antisense RNA oligonucleotides targeting miRNAs and demonstrated the potential inhibition of adipocyte differentiation by a mir-143 antagonim.

**Epigenetic regulation in diabetes**

Epigenetic modulating mechanisms have recently been established as a massive regulatory machine that cannot be ignored in searching for a new mechanistic understanding of metabolic syndrome, obesity and type 2 diabetes [50]. Type 2 diabetes is typically characterized by a combination of peripheral insulin resistance with an insulin secretion defect that varies in severity. The known mechanisms for disrupted insulin secretion in type 2 diabetes include accumulated damage caused by hyperglycaemia, hyperlipidaemia and oxidative stress in combination [51,52]. Oxidative stress and reactive oxygen species have been shown to directly affect DNA methylation pattern and histone organization, therefore tuning the expression of multiple genes [53]. In addition, early nutritional status and possible intrauterine deprivation of nutrients have been shown to strongly impact the long-lasting DNA methylation effects directed at the genome readout [54] with immediate effects on development. A proposed mechanism includes effects by dietary methyl and cofactor sources, such as vitamin B12 and folic acid [55] linked to single-carbon metabolism providing the methyl groups for all biological methylation reactions. During embryonic development, the genome undergoes extensive demethylation followed by remethylation, and appropriate DNA methylation status must be maintained over the rounds of rapid cellular proliferation steps [56]. Unbalanced methyl donors from nutrition during embryonic development may thus irreversibly affect the DNA methylation patterns [57]. Therefore, extremes of nutritional availability and distinct environmental factors have been suggested to influence the epigenetic modifications in human genome and to enhance susceptibility to altered epigenetic pattern and later to metabolic disorders and adult chronic diseases [58]. Epidemiological studies have indicated that sub- or super-optimal nutrient provision in utero may lead to specific chromatin modifications as described above and have been proposed as mechanisms associated with the worldwide epidemic of type 2 diabetes [59]. To support this hypothesis, dietary protein restriction of pregnant rats typically associated with hypomethylation of e.g. the glucocorticoid receptor (GR) and peroxisome proliferator-activated receptor gamma (PPARγ) [60]. PPARγ coactivator 1 α (protein PGC-1α, gene PPARγ1α) is a well-established node in the pathogenesis of diabetes and a master transcriptional coactivator of mitochondrial genes [61]. Its expression is decreased and related to impaired ATP production as a consequence of reduced oxidative phosphorylation in patients with type 2 diabetes. It has also been reported that DNA methylation of the PPARγ1α promoter is increased in diabetic islets, demonstrating a plausible mechanism for reduced PPARγ1α mRNA expression and insulin secretion in pancreatic islets of patients with type 2 diabetes [62]. Consequently, super-optimal methyl donors from nutrition may influence DNA methylation in the PPARγ1α promoter region and therefore represent a potential epigenetic cause for type 2 diabetes. Heterochromatin silencing and
histone H3-K9 methylation of heterochromatin transcription and generation of heterochromatin-originated short interfering RNA (siRNA) molecules have been shown in fission yeasts [63]. This epigenetic regulation has specifically been timed during the S-phase of the cell cycle in a temperature sensitive manner. In mammals, levels of DNA methylation correlate with age [64]. This suggests that gene expression may be repressed over time. It has been shown that in the glomerulus ageing podocytes exhibit changed gene expression patterns [65]. In addition, it has been shown that the developmental regulator Pax2 promotes assembly of an H3K4 methyltransferase complex through nuclear factor PTIP (Pax Transcription activation domain Interacting Protein) [66]. The PTIP complex localizes to a Pax2 DNA-binding sequence and recruits the methyltransferase complex. In the embryo, together, Pax2 and Pax8 are important to regulators inducing nephric structures in the intermediate mesoderm and urogenital epithelium [67]. Therefore, Pax2 provides a kidney-specific locus for epigenetic modifications during development.

In addition, it has been shown that some genes that become DNA hypermethylated and silenced in cancer cells require intact Dicer function for the maintenance of their epigenetic status [68]. These results support the hypothesis that RNA interference-mediated DNA methylation in cooperation with environmental responses modify the genetic risk factors and the epigenetic inheritance of heterochromatin.

**MicroRNAs in insulin release regulation and kidney actions**

A subset of miRNAs has shown to be involved in metabolic regulation of glucose homeostasis (Table 1). However, only very few miRNA species have been fully characterized experimentally and most of their functions remain unknown. Pancreatic islet-specific miR-375 inhibits insulin secretion in mouse pancreatic β-cells by inhibiting the expression of the protein myotrophin [69]. In addition, myotrophin, also known as V-1, has been shown to interact with an actin-capping protein inhibiting F-actin assembly, and to induce exocytosis of insulin granules [69]. In another study, increasing the level of miR-9 resulted in a severe defect in glucose-stimulated insulin release by down-regulating the transcription factor OneCut2 (OC2) [70]. OC2 represses the activity and expression of Rab27a effector granophilin, which is a key component of the machinery controlling insulin release [71]. Also miR-192 levels have been shown to be increased in glomeruli isolated from streptozotocin-injected diabetic mice as well as diabetic mice db/db when compared to non-diabetic mice [24]. MiR-192 was shown to regulate E-box repressors that are responsible for controlling TGF-β induced extracellular matrix proteins collagen 1-α 1 and 2 (Col1a1 and 2) expression [24]. Col1a1 and 2 were shown to accumulate during diabetic nephropathy; therefore, these results suggest an potential role of miR-192 in kidney diseases.

Recently, a correlation between elevated Notch signalling pathway gene expression and diabetic nephropathy has been shown, in concert with Gremlin, the gene associated with tubulointerstitial fibrosis in diabetic nephropathy [72], suggesting the presence of miRNAs and CpG islands as a potential regulatory strategy in this disease [73]. Interestingly, distinct miRNAs appear to modify Notch pathways in Drosophila melanogaster with an effect in signalling cascades determining cell specification and development [74]. Lai et al. showed that specific miRNAs regulated negative regulatory sequence motifs known as the GY box, the Brd box and the K box in the 3′ UTR of the Notch target genes [74]. These regulatory boxes have been shown to serve as binding sites for miRNAs: GY-box is inhibited by miR-7, Brd-box by miR-4 and miR-79, K-box by miR-2 and miR-11; however, it remains to be determined whether these miRNAs regulate Notch signalling in diabetic nephropathy. MiR-143 has been experimentally shown to regulate genes that are crucial for adipocyte differentiation, (including GLUT4, HSL, fatty acid-binding protein aP2 and PPAR-γ2) demonstrating a role for miRNAs in fat metabolism and in endocrine function in humans [49]. In addition, miR-15 and miR-16 have been proposed to control the Wnt/β-catenin signalling pathway during the embryonal stage [75]. Wnt/β-catenin signalling regulates the early events of nephrogenic induction during mouse kidney development [76]; however, a regulatory role for miR-15 or -16 has not yet been determined during this process.

In the human kidney cortex, the renal glomerulus forms the biological sieve that allows the passage of water and small molecules while macromolecules e.g. albumin cannot normally pass beyond the filtration barrier [77]. Podocytes surround the basement membrane of glomerular capillaries from the outside and present specialized structures, foot processes linked to each other forming the slit diaphragms [78]. Therefore podocytes are considered to be critical for maintaining the functional filtration barrier and preventing albuminuria: alterations in slit diaphragm-associated genes result in severe proteinuria [77].

While the association of podocyte miRNA and DNA methylation profiles in health and disease is an important topic to study, little is still known of the role of miRNAs for this complex. General differences in miRNA expression as well as in the proteome profile have been shown in the rat renal medulla and in the renal cortex region using the microRNA microarray [40]. Very recent findings of podocyte-specific deletion of Dicer demonstrated a critical role for miRNA regulation in the progression of glomerular and tubular damage, and therefore the development of proteinuria [79,80]. Dicer deletion in podocytes led to podocyte apoptosis and depletion; proteinuria was significant 3 weeks after birth in mouse models. Also the rapid progression of glomerular and tubular injury was prominent at week 3, and culminated in death several weeks later. Based on altered gene expression profile in podocyte-specific Dicer knock-down glomeruli, especially the miR-30 family has been highlighted as candidates participating in podocyte homestasis and pathogenesis of kidney diseases of podocyte origin. In another study with the podocyte-specific Dicer knock-out mice, it was noticed that expression of slit diaphragm proteins nephrin and podocin was decreased [81–83]. In this study, mmu-miR-23b, mmu-miR24 and mmu-miR26a were implicated as critical to maintain the glomerular filtration barrier [81].
The rapid emergence and advances in high throughput screening techniques facilitated focused research of both genome-wide and cell-specific epigenetic and post-transcriptional imprints in diabetes and kidney disease. Improved understanding and identification of new epigenetic and post-transcriptional regulatory mechanisms involved in the regulation of the key molecular complexes of podocytes will be of utmost importance in advancing diagnosis and novel biomarker development, and in future therapeutics.

Acknowledgements. This study was supported by European Union FP6-Lifescihealth-7 (DiaNa), The Sigrid Juselius Foundation of Finland and Science Foundation Ireland.

Conflict of interest statement. None declared.

References
1. Dimitri P, Corradini N, Rossi F et al. The paradox of functional heterochromatin. Bioessays 2005; 27: 29–41
2. Heitz E. Das heterochromatin der Moose. Jezb. Wiss Botanik 1928; 69: 762–818
3. Elgin SC, Grewal SI. Heterochromatin: silence is golden. Curr Biol 2003; 13: R895–R898
4. Bails JM, Forshulg SL. Phase assembly of centromeric heterochromatin and cohesion. Cell Cycle 2004; 3: 416–418
5. Piacentini L, Fanti L, Berloco M et al. Heterochromatin protein 1 (HP1) is associated with induced gene expression in Drosophila euchromatin. J Cell Biol 2003; 161: 707–714
6. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 2005; 15: 490–495
7. Takai D, Jones PA. The CpG island searcher: a new WWW resource. In Silico Biol 2003; 3: 235–240
8. Bird A. DNA methylation patterns and epigenetic memory. Science 2002; 293: 784–788
9. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168–174
10. Eden A, Gaudet F, Waghmare A et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300: 455
11. Saxonov S, Berg P, Bruttig DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 2006; 103: 1412–1417
12. Jenewein T, Allis CD. Translating the histone code. Nat Struct Mol Biol 2003; 10: 458–465
13. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006; 31: 89–97
14. Kawasaki H, Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 2004; 431: 211–217
15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297
16. Georgetzas BW 3rd, Hildreth R, Morisot S et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104: 2750–2755
17. Cimmino A, Calin GA, Fabbri M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944–13949
18. Zhao Y, Srivistava D. A developmental view of microRNA function. Trends Biochem Sci 2007; 32: 189–197
19. Miranda KC, Huynh T, Tay Y et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126: 1203–1217
20. Perera RJ, Ray A. MicroRNAs in the search for understanding human diseases. Bioscience 2007; 21: 97–104
21. Kato M, Zhang J, Wang M et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGβ-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 2007; 104: 3432–3437
22. Cullen BR. Transcription and processing of human microRNA precursors. Mol Cell 2004; 16: 861–865
23. Bohnsack MT, Czapinski K, Gorlich D. Exportin 5 is a Ran-GTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004; 10: 185–191
24. Macrae IF, Zhou K, Li F et al. Structural basis for double-stranded RNA processing by Dicer. Science 2006; 311: 195–198
25. Tomari Y, Matranga C, Haley B et al. A protein sensor for siRNA asymmetry. Science 2004; 306: 1377–1380
26. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008; 9: 219–230
27. Nottrott S, Simard MJ, Richter JD. Human let-7a miRNA blocks protein production on actively translating polyribosomes. Nat Struct Mol Biol 2006; 13: 1108–1114
28. Humphreys DT, Westman BJ, Martin DI et al. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci USA 2005; 102: 16961–16966
29. Liu J, Valencia-Sancheza MA, Hannon GJ et al. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 2005; 7: 719–723
30. Romao I, Roth J. Genetic and environmental interactions in obesity and type 2 diabetes. J Am Diet Assoc 2008; 108: S24–S28
31. Hanson MA, Gluckman PD. Developmental origins of health and disease: new insights. Basic Clin Pharmacol Toxicol 2008; 102: 90–93
32. Gresham D, Dunham MJ, Botstein D. Comparing whole genomes using DNA microarrays. Nat Rev Genet 2008; 9: 291–302
33. Shi H, Maier S, Nimmrich V et al. Oligonucleotide-based microarray for DNA methylation analysis: principles and applications. J Cell Biochem 2008; 103: 138–143
34. Ho SM, Tang WY. Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases. Reprod Toxicol 2007; 23: 267–282
35. Dannenberg LO, Edenberg HJ. Epigenetics of gene expression in human hematopoietic cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 2006; 7: 181
36. Lewis BP, Shih IH, Jones-Rhoades MW et al. Prediction of mammalian microRNA targets. Cell 2003; 115: 787–798
37. Tian Z, Greene AS, Pietrusz L et al. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res 2008; 18: 404–411
38. Griffiths-Jones S, Saini HK, von Dongen S et al. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008; 36: D154–D158
39. Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet 2008; 24: 133–141
40. Kuhn DE, Martin MM, Feldman DS et al. Experimental validation of microRNA targets. Methods 2008; 44: 47–54
41. Tang F, Hajkova P, O’Carroll D et al. MicroRNAs are tightly associated with RNA-induced gene silencing complexes in vivo. Biochem Biophys Res Commun 2008; 372: 24–29
42. Esaú CC. Inhibition of microRNA with antisense oligonucleotides. Methods 2008; 44: 55–60
43. Davis S, Lollo B, Freier S et al. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006; 34: 2294–2304
44. Zamaratski E, Pradeepkumar PI, Chattopadhyaya J. A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as
substrate for RNase H. J Biochem Biophys Methods 2001; 48: 189–208

48. Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005; 438: 685–689

49. Esau C, Kang X, Peralta E et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004; 279: 52361–52365

50. Junien C, Nathanielsz P. Report on the IASO Stock Conference 2006: early and lifelong environmental epigenomic programming of metabolic syndrome, obesity and type II diabetes. Obes Rev 2007; 8: 487–502

51. Wallace TM, Matthews DR. Coefficient of failure: a methodology for examining longitudinal beta-cell function in type 2 diabetes. Diabet Med 2002; 19: 465–469

52. Robertson RP, Harmon J, Tran PO et al. Glucotoxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52: 581–587

53. Cerda S, Weitzman SA. Influence of oxygen radical injury on DNA methylation. Mutat Res 1997; 386: 141–152

54. Gallou-Kabani C, Junien C. Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetologia 2005; 48: 1899–1906

55. Van Den Veyver IB. Genetic effects of methylation diets. Annu Rev Nutr 2002; 22: 255–282

56. Morgan HD, Santos F, Green K et al. Epigenetic reprogramming in mammals. Hum Mol Genet 2005; 14: R47–R58

57. Waterland RA, Garza C. Potential mechanisms of metabolic imprinting that lead to chronic disease. Am J Clin Nutr 1999; 69: 179–197

58. Feil R. Environmental and nutritional effects on the epigenetic regulation of genes. Mutat Res 2006; 600: 46–57

59. Devaskar SU, Thamotharan M. Metabolic programming in the pathogenesis of insulin resistance. Rev Endocr Metab Disord 2007; 8: 105–113

60. Simmons RA. Developmental origins of beta-cell failure in type 2 diabetes: the role of epigenetic mechanisms. Pediatr Res 2007; 61: 64R–67R

61. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 2008; 88: 611–638

62. Ling C, Del Guerra S, Lupi R et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetes 2007; 56: 615–622

63. Kloc A, Zaratiegui M, Nora E et al. RNA interference guides histone modification during the S phase of chromosomal replication. Curr Biol 2008; 18: 490–495

64. Fraga MF, Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet 2007; 23: 413–418

65. Wiggins JE, Goyal M, Sanden SK et al. Podocyte hypertrophy, “adaptation,” and “decompensation” associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol 2005; 16: 2953–2966

66. Patel SR, Kim D, Levitan I et al. The BRCT-domain containing protein PTIP links PAX2 to a histone H3, lysine 4 methyltransferase complex. Dev Cell 2007; 13: 580–592

67. Bouchard M, Souabni A, Mandler M et al. Nephrine lineage specification by Pax2 and Pax9. Genes Dev 2002; 16: 2958–2970

68. Ting AH, Suzuki H, Cope L et al. A requirement for DICER to maintain full promoter CpG island hypermethylation in human cancer cells. Cancer Res 2008; 68: 2570–2575

69. Poy MN, Eliasson L, Krutzfeldt J et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004; 432: 226–230

70. Plaisance V, Abderrahmani A, Perret-Menoud V et al. MicroRNA-9 controls the expression of Granulin/Spl4p and the secretory response of insulin-producing cells. J Biol Chem 2006; 281: 26932–26942

71. Gomi H, Mizutani S, Kasai K et al. Granulophore molecularly docks insulin granules to the fusion machinery. J Cell Biol 2005; 171: 99–109

72. Dolan V, Murphy M, Sadlier D et al. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis 2005; 45: 1034–1039

73. Walsh DW, Roxburgh SA, Mcgettigan P et al. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. Biochim Biophys Acta 2008; 1782: 10–21

74. Lai EC, Tan B, Rubin GM. Pervasive regulation of Drosophila Notch target genes by GY-box-, Bdh-box-, and K-box-class microRNAs. Genes Dev 2005; 19: 1067–1080

75. Martello G, Zacchigna L, Inui M et al. MicroRNA control of Nodal signalling. Nature 2007; 449: 183–188

76. Park JS, Valerius MT, McMahon AP. Wnt/beta-catenin signalling regulates nephrin induction during mouse kidney development. Development 2007; 134: 2533–2539

77. Patari-Sampo A, Ihalmo P, Hollohofer H. Molecular basis of the glomerular filtration: nephrin and the emerging protein complex at the podocyte slit diaphragm. Am J Pathol 2006; 38: 483–492

78. Rodewald R, Karnovsky MJ. Porous substrate of the glomerular slit diaphragm in the rat and mouse. J Cell Biol 1974; 60: 423–433

79. Shi S, Yu L, Chiu C et al. Podocyte selective deletion of Dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol 2008; 19: 2159–2169

80. Harvey SJ, Jarad G, Cunningham 3 et al. Podocyte-specific deletion of Dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol 2008; 19: 2150–2158

81. Ho J, Ng KH, Rosen S et al. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol 2008; 19: 2069–2075

82. Holzman LB, St John PL, Kovari IA et al. Nephrin localizes to the slit pore of the glomerular epithelial cell. Kidney Int 1999; 56: 1481–1491

83. Roselli S, Gribouval O, Boute N et al. Podocin localizes to the slit diaphragm area. Am J Pathol 2002; 160: 131–139

84. Chen L, Al-Awqati Q. Segmental expression of Notch and hairy genes in nephrogenesis. Am J Physiol Renal Physiol 2005; 288: F939–F952

85. Huang TH, Laux DE, Hamlin BC et al. Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. Cancer Res 1997; 57: 1030–1034

86. Hayashizaki Y, Hirotsune S, Okazaki Y et al. Restriction landmark genomic scanning method and its various applications. Electrophoresis 1993; 14: 251–258

87. Toyota M, Ho C, Ahiuja N et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59: 2307–2312

88. Huang TH, Perry MR Laux DE. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999; 8: 459–470

89. Frommer M, McDonald LE, Millar DS et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992; 89: 1827–1831

90. Gitan RS, Shi H, Chen CM et al. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res 2002; 12: 158–164

91. Cross SH, Charlton JA, Nan X et al. Purification of CpG islands using a methylated DNA binding column. Nat Genet 1994; 6: 236–244

92. Oberley MJ, Tsao J, Yau P et al. High-throughput screening of chromatin immunoprecipitates using CpG-island microarrays. Methods Enzymol 2004; 376: 315–334

93. Tost J, Schatz P, Schuster M et al. Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry. Nucleic Acids Res 2003; 31: e50.